US2013253071A1PendingUtilityA1

Methods and Compositions for Prevention and Treatment of Inflammatory Disease, Autoimmune Disease and Transplant Rejection

Assignee: UNIV CALIFORNIAPriority: Nov 2, 2001Filed: Mar 14, 2013Published: Sep 26, 2013
Est. expiryNov 2, 2021(expired)· nominal 20-yr term from priority
Inventors:Michael David
A61P 37/06A61P 37/02A61P 29/00A61P 25/00A61P 31/00A61P 11/06A61K 31/09A61K 31/085A61K 31/70A61K 31/704A61P 1/00A61K 31/135A61K 31/7028A61K 31/05
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.

Claims

exact text as granted — not AI-modified
1 - 39 . (canceled) 
     
     
         40 . A method for reducing one or more symptoms of asthma in a subject in need thereof, wherein said method comprises administering to said subject a pharmaceutically effective amount of purified piceatannol, wherein said subject is selected from the group consisting of human, mouse and canine. 
     
     
         41 . The method of  claim 40 , wherein said administering is intranasal. 
     
     
         42 . The method of  claim 40 , wherein said administering is before manifestation of one or more symptoms of asthma. 
     
     
         43 . The method of  claim 40 , wherein said administering is concomitant with manifestation of one or more symptoms of asthma. 
     
     
         44 . The method of  claim 40 , wherein said administering is after manifestation of one or more symptoms of asthma.

Join the waitlist — get patent alerts

Track US2013253071A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.